产品说明书

Milnacipran ((1S-cis) HCl)

Print
Chemical Structure| 175131-60-9 同义名 : 左旋米那普林 ;Levomilnacipran hydrochloride;Levomilnacipran (hydrochloride);(1S-cis)-Milnacipran;F-2695 hydrochloride;Milnacipran ((1S-cis) hydrochloride)
CAS号 : 175131-60-9
货号 : A436777
分子式 : C15H23ClN2O
纯度 : 98%
分子量 : 282.809
MDL号 : MFCD18433402
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 50 mg/mL(176.8 mM)
动物实验配方：
生物活性
描述 Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite[3]. (1S-cis)-Milnacipran Hydrochloride is the latest antidepressants approved for the treatment of MDD. It acts through an increased serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT). In addition to the SSRI activity, (1S-cis)-Milnacipran Hydrochloride is also a norepinephrine reuptake inhibitor[4]. In seven randomised, double-blind clinical trials, levomilnacipran is generally more effective than placebo for the treatment of MDD in the short-term. Preliminary evidence suggests that levomilnacipran extended release may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life)[5].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.54mL

0.71mL

0.35mL

17.68mL

3.54mL

1.77mL

35.36mL

7.07mL

3.54mL
参考文献

[1]Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014 Dec;15(17):2525-42.

[2]Vaishnavi SN, Nemeroff CB, et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2.

[3]Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065

[4]Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. J Affect Disord. 2018;228:1‐12

[5]Bruno A, Morabito P, Spina E, Muscatello MR. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol. 2016;14(2):191‐199